Evgen Pharma PLC AGM Statement (9072F)
18 Luglio 2019 - 8:00AM
UK Regulatory
TIDMEVG
RNS Number : 9072F
Evgen Pharma PLC
18 July 2019
For immediate release 18 July 2019
Evgen Pharma plc
("Evgen" or "the Company")
AGM Statement
Evgen Pharma (AIM: EVG), a clinical stage drug development
company focused on the treatment of cancer and neurological
conditions, will hold its Annual General Meeting ("AGM") later
today. At the AGM, the Company's Chairman, Barry Clare, will make
the following statement.
"We continue to make significant progress in establishing Evgen
as a world leader in sulforaphane-based pharmaceuticals.
"In March this year we announced that our lead product, SFX-01,
had met its primary endpoints in an open label Phase 2 trial of
SFX-01 in metastatic breast cancer. The trial data confirmed that
SFX-01 is a highly promising anti-cancer agent with an excellent
tolerability profile. We are making good progress in planning the
next clinical trial in metastatic breast cancer, focusing on the
anticipated use of SFX-01 as a second line therapy where the market
opportunity is substantial.
"The announcement of the final read-out of our Phase 2 trial of
SFX-01 in subarachnoid haemorrhage remains in line with earlier
guidance of Q3 or early Q4 of this calendar year. We are excited by
the outcome of this blinded study in an indication where there has
been no significant clinical advance in more than 20 years.
"Further anticipated near-term news flow includes the
announcement of secondary data and additional insights from the
metastatic breast cancer trial at the ESMO 2019 conference in
Barcelona in the early autumn.
"The GBP5m equity placing completed earlier this year has given
us the financial resources to support the continued development of
our programmes, in particular, further toxicology work to enable
support for investigator-led clinical trials, and a scale-up ready
product formulation, giving us confidence in the year ahead."
A short presentation will be given to shareholders at the AGM.
The presentation will contain no new material information and will
be made available later today on the Company website, here:
http://evgen.com/investors/shareholder-information/
Separately, we would like to announce that Evgen has appointed
Walbrook PR and, from hereon in, they will be supporting our PR
efforts as we enter the next stage of our development. We are very
grateful to Buchanan for the strong support they have provided over
the past few years.
Enquiries:
Evgen Pharma plc c/o +44 (0) 20 7466 5000
Dr Stephen Franklin, CEO
Richard Moulson, CFO
www.evgen.com
finnCap
Geoff Nash, Teddy Whiley (Corporate
Finance)
Alice Lane, Manasa Patil (ECM)
www.finncap.com +44 (0) 20 7220 0500
WG Partners LLP
Nigel Barnes, Claes Spång +44 (0) 20 3705 9330
Buchanan
Mark Court, Sophie Wills, Tilly
Abraham
evgen@buchanan.uk.com +44 (0) 20 7466 5000
Notes for editors:
About Evgen Pharma plc
Evgen Pharma is a clinical stage drug development company whose
lead programmes are in breast cancer and subarachnoid haemorrhage,
a type of stroke. The Company's core technology is Sulforadex(R), a
method for synthesising and stabilising the naturally occurring
compound sulforaphane and novel proprietary analogues based on
sulforaphane. The lead product, SFX-01, is a patented composition
of synthetic sulforaphane and alpha-cyclodextrin.
The Group commenced operations in January 2008 and has its
headquarters at The Colony, Wilmslow, Cheshire, and its registered
office is at the Liverpool Science Park, Liverpool. It joined the
AIM market of the London Stock Exchange in October 2015 and trades
under the ticker symbol EVG.
For further information, please visit: www.evgen.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
AGMRRMBTMBBBTRL
(END) Dow Jones Newswires
July 18, 2019 02:00 ET (06:00 GMT)
Grafico Azioni Evgen Pharma (LSE:EVG)
Storico
Da Giu 2024 a Lug 2024
Grafico Azioni Evgen Pharma (LSE:EVG)
Storico
Da Lug 2023 a Lug 2024